ImmunityBio (IBRX) Shares Outstanding (2013 - 2026)

ImmunityBio (IBRX) has 14 years of Shares Outstanding data on file, last reported at $1.0 billion in Q1 2026.

• Quarterly Shares Outstanding rose 22.7% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 22.7% YoY) and the FY2025 annual result came in at $1.0 billion, up 18.63% from the prior year.
• Shares Outstanding climbed to $1.0 billion in Q1 2026 per IBRX's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Shares Outstanding topped out at $1.0 billion in Q1 2026 and bottomed at $398.0 million in Q1 2022.
• The 5-year median for Shares Outstanding is $677.0 million (2024), against an average of $680.3 million.
• The widest annual swing landed in 2022, when Shares Outstanding advanced 1.47%; it then surged 66.8% in 2023.
• Tracing IBRX's Shares Outstanding over 5 years: stood at $421.6 million in 2022, then soared by 59.14% to $670.9 million in 2023, then rose by 27.13% to $852.9 million in 2024, then advanced by 18.63% to $1.0 billion in 2025, then advanced by 3.51% to $1.0 billion in 2026.
• Per Business Quant, the three latest IBRX Shares Outstanding figures stand at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $985.0 million (Q3 2025).

Peer Comparison